On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > ORGANIZATION
ORGANIZATION
- JMA’s New Pharma Affairs Exec Wants More Stringent Rules on Sakigake, Conditional Approval
August 11, 2020
- Bayer Yakuhin President Heike Prinz Elected New EFPIA Japan Chief
August 3, 2020
- Japan Ob-Gyn Society Lauds Approval of 9-Valent HPV Vaccine, Plaintiffs Renew Protest
July 27, 2020
- Pharmacist Group Says Drug Price Survey This Year “Utterly Unacceptable”
July 21, 2020
- Expand Self-Medication Tax Break and Make It Permanent: Industry Groups
July 20, 2020
- Trade Group Urges Drug Makers to Fully Provide Info on Stock-Outs, Supply Curbs
July 20, 2020
- JPMA Reiterates It’s Not the Right Time for Off-Year Drug Price Survey
July 17, 2020
- Number of Contract Sales Reps Up 10.8% to 3,445, with New Drug Launches
July 17, 2020
- JMA Chief Says Off-Year Price Survey “Technically Impossible”, JPA President Meets PM
July 16, 2020
- Japan Red Cross Presses ahead with Joint Purchase of Drugs Selected under Formularies at Group Hospitals
July 15, 2020
- AMR Action Fund Would Help Deal with Threat While We Still Have Time: IFPMA Vice Pres.
July 14, 2020
- JMA Reiterates Concerns for Off-Year Drug Price Survey after Govt’s Honebuto Draft Revealed
July 13, 2020
- Mobile Pharmacy Van Set in Motion as Kumamoto Downpour Hits Local Stores, Some Wholesalers
July 8, 2020
- Wholesaler Group Makes Emergency Plea against Off-Year Drug Price Survey
July 7, 2020
- Expand Self-Medication Tax Break to Cover All Non-Prescription Drugs: OTC Group
July 6, 2020
- Stop Patient Enrollment in Avigan Studies: Drug Damage Watchdog
July 3, 2020
- Drug Makers Joining Forces to Share Manufacturing Capacities, Accelerate COVID-19 Programs: PhRMA CMO
July 2, 2020
- COVID-19 Having “Serious Impact” on New Drug Development; JPMA Calls for Strong Systems for Emergencies
July 2, 2020
- Generic Use Rate at 76.9% in FY2019, 78.5% in Jan.-March 2020: JGA
July 1, 2020
- Toshio Nakagawa Elected as New Chief of Japan Medical Association
June 29, 2020
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…